BME:ROVIPharmaceuticals
Assessing Laboratorios Farmaceuticos Rovi (BME:ROVI) Valuation After 2025 Results Dividend Hike And 2026 Guidance
Earnings, dividend proposal and guidance at a glance
Laboratorios Farmaceuticos Rovi (BME:ROVI) has drawn fresh attention after releasing its 2025 results, proposing a higher cash dividend and reaffirming its 2026 operating revenue guidance. This provides investors with updated information on profitability and capital returns.
See our latest analysis for Laboratorios Farmaceuticos Rovi.
The earnings release and dividend proposal come after a strong run in the shares, with a 30 day share price...